CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Minerva Neurosciences, Inc. (NERV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Minerva Neurosciences, Inc. (NERV)

Pharmaceutical Preparations · market cap $172M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Minerva Neurosciences (NERV) is a ~$105M market-cap pharmaceutical company (~47.7M shares, ~$2.2/share) whose lead asset in our data is roluperidone, in Phase 3 for negative symptoms of schizophrenia. Our data also lists MIN-117 (Phase 2, Major Depressive Disorder). Cash is $24.7M with a reported runway of ~16.9 months, and the only catalyst on our calendar is an estimated Q3 earnings report on 2026-11-04.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
MIN-117Phase 2Major Depressive Disorder
RoluperidonePhase 3Negative Symptoms of Schizophrenia
Price & technical context
3-month
-48.0%
6-month
-55.9%
12-month
-42.5%
52-wk range
$2.20–$8.07
vs 50-day MA
-23.6%
vs 200-day MA
-52.2%
Realized vol
90.1%
Max drawdown
-72.7%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for NERV (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.